SURF News and Press, Surface Oncology Inc. From 09/20/21

AstraZeneca (NASDAQ: AZN) and Surface Oncology (NASDAQ: SURF) shares both traded up on Monday, bucking the heavily bearish trend of the overall stock market. AstraZeneca closed the day more than 5% higher on the back of positive news about its cancer drug, while Surface Onco...

Palm Beach, FL – September 20, 2021 – FinancialNewsMedia.com News Commentary – Over the last decade, the radiotherapy devices market has seen significant technological advancements. These advancements have helped in the development of more effective, low-cos...

Corvus Pharmaceuticals (NASDAQ:CRVS) +56%. Innate Pharma (NASDAQ:IPHA) +32% Monalizumab data from COAST trial presented at ESMO Congress 2021 Surface Oncology (NASDAQ:SURF) +14%. BeiGene (NASDAQ:BGNE) +13% on positive DKN-01 + tislelizumab data in gastroesophageal cancer AbCell...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, trader! There’s only one day of trading left so let’s start it off right with a look at the biggest pre-market stock movers for Friday. Source: ventdusud / Shutterstock.com We’re s...

The following slide deck was published by Surface Oncology, Inc. in conjunction with this event. For further details see: Surface Oncology (SURF) Investor Presentation - Slideshow

Surface Oncology (NASDAQ:SURF): Q2 GAAP EPS of -$0.44 misses by $0.09. Revenue of $0.51M misses by $2.45M. As of June 30, 2021, cash, cash equivalents and marketable securities were $164.3 million, compared to $175.1 million on December 31, 2020. Financial Outlook: Surface Oncology continues ...

SRF388, a First-in-Class Anti-IL-27 Antibody, Demonstrates Monotherapy Activity in Ongoing Phase 1 Study; Enrollment Continues for Phase 2 Monotherapy Expansion and Combination Cohorts SRF617, a CD39 Inhibitor, Demonstrates Good Tolerability in Ongoing Phase 1 Study; Phase 2 Dos...

Surface Oncology is an early-stage cancer therapeutics company with five assets in development. However, only 3/5 have hit clinical trials and early clinical trial results have been disappointing. Licenses to GSK and Novartis and current enterprise valuation increase attractivenes...

CAMBRIDGE, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Denice Torres will join the company’s board of dir...

Senseonics Holdings SENS +34% on the study results for glucose monitoring system.Windtree Therapeutics (WINT) +28%.The9 Limited NCTY +18% on Montcrypto acquisition.SemiLEDs Corporation (LEDS) +16%.Q&K International Group Limited (QK) +15%.Core Laboratories N.V. (CLB) +...